PQ Completes Acquisition of Sibelco's Specialty Silicate Business in Sweden
PQ (www.pqcorp.com), a leading global producer of silicates, silicas and derivative products, announced that it has completed the acquisition of the specialty silicate business of the Sibelco Group currently operated in the Lödöse plant in Sweden.
“PQ is pleased to complete this transaction with Sibelco and we are excited to begin offering our products and service to new customers in the region,” said Al Beninati, CEO of PQ. “Our robust European network and expertise in specialty silicates will enable our new customers to achieve growth across the Nordics.”
About PQ
With headquarters in Malvern, Pennsylvania PQ is a leading global provider of silicates, silicas and derivative products. PQ’s products are found in a wide variety of industries and many aspects of everyday life, from decorative paints to green cement, from clean drinking water to green tires and from toothpaste to aiding in the production of biofuels and beer. Supported by 1,500 employees across 30 facilities in 13 countries, PQ serves more than 900 customers around the world.
Through its global network of 30 facilities, PQ provides best-in-class product offerings that support a broad range of end uses including silica and chemical manufacturing; paints and coatings; purification, construction and drilling; and personal care, nutrition, and food and beverage.
About Sibelco
Sibelco is a global leader in material solutions. Sibelco mines, processes and sells specialty industrial minerals – in particular high purity quartz, silica, clays, feldspathics and olivine – and is a leader in glass recycling. Sibelco’s solutions promote the progress of modern life and serve industries as diverse as glass, ceramics, construction, coatings, polymers, water purification and others. The Sibelco Group has production facilities in more than 30 countries and a team of some 5,000 people. Learn more at www.sibelco.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250112444104/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bynder Showcases Its New and Expanded AI Capabilities at NRF to Help Retailers Drive Personalized Content Experiences13.1.2025 12:24:00 CET | Press release
Bynder, a global leader in AI-powered enterprise DAM, is showcasing its latest AI innovations at the NRF retail show in New York. These new innovations build on the company’s already extensive set of AI capabilities, to help power global brands to drive personalized content experiences. During the show, Bynder revealed its Natural Language Search functionality which will help DAM users find images quickly by simply describing them in all major languages. Bynder already has more than 500 customers leveraging its existing AI Search capabilities such as similarity search, text in image and facial recognition. In addition to this, Bynder launched its next generation Duplicate Image Finder which helps organize and maintain a brand’s DAM by detecting and removing duplicate images at the touch of a button. This enhanced feature is now AI assisted to detect exact duplicate images with greater accuracy and allow administrators to easily delete them from the DAM. For retailers that include video
Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs13.1.2025 12:15:00 CET | Press release
This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address the full range of product requirements. In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide have announced a partnership that combines Cytovance’s expertise in microbial and mammalian expression, process development and cGMP manufacturing with PolyPeptide’s capabilities in complex peptide development and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113598664/en/ Axel Schleyer, CCO of Cytovance Biologics: “Cytovance has been supporting the development and scale-up of microbial and mammalian-expressed biologics for two decades. Combining our strengths with PolyPeptide’s is exactly what our customers and the industry need to support the rapidly advancing market demand.”
Transition Industries and Veolia Partner to Redefine Industrial Water Use at the Pacifico Mexinol Project in Mexico13.1.2025 09:24:00 CET | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, and Veolia Water Technologies & Solutions, world leader in water technology, have signed an agreement to explore the provision of advanced industrial water technology for the Pacifico Mexinol project in Sinaloa, Mexico. Expected to initiate operations in 2028, Pacifico Mexinol is poised to be the world’s largest standalone ultra-low carbon chemical production facility in the world, with an output of 6,145 metric tons of methanol (MT) per day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250112655528/en/ The memorandum of understanding (MOU) outlines the collaboration between Transition Industries and Veolia to develop a purpose-driven water strategy for the Pacifico Mexinol project. Designed with Ahome Municipality’s Drinking Water and Sewage Board (JAPAMA), this strategy would make the Pacifico Mexinol site one
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer13.1.2025 09:00:00 CET | Press release
Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of expertise as Egle transitions into the clinic its two lead drug candidates, EGL-001 and EGL-003. “I am thrilled to join Egle Therapeutics and collaborate with a team renowned for its deep scientific expertise in regulatory T cells and its strong track record in developing innovative drug candidates for immunology and oncology,” said Christophe Quéva, Ph.D. “Egle is uniquely positioned to demonstrate the therapeutic potential of harnessing regulatory T cells for treating both cancer and autoimmune diseases.” “As we transition from a company with preclinical assets to a fully-fledged clinic
Avanzanite Bioscience Announces Appointment of Chief Technical Officer to Accelerate European Expansion and Drive Growth13.1.2025 07:00:00 CET | Press release
Appointment of Jason Cameron as first Chief Technical Officer underscores Avanzanite’s strategic commitment to accelerating revenue growth and expanding its footprint across Europe and beyond. With over 25 years of global pharmaceutical experience, Cameron is poised to enhance Avanzanite’s commercial distribution of orphan medicines and fuel the company’s ambitious growth trajectory. In the short term, Cameron will focus on deepening Avanzanite’s presence in 26 European countries and spearheading the execution of strategic partnerships slated for 2025. Avanzanite Bioscience B.V., a leading commercial-stage specialty pharmaceutical company committed to bringing ground-breaking medicines for rare diseases to market, announced today the appointment of Jason Cameron as Chief Technical Officer (CTO). This move marks a significant step in Avanzanite’s mission to accelerate growth, expand its presence in Europe, and advance the company’s next phase of international partnerships and product la
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom